Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 287

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 287
---
 ultimate realization of the deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible
and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of
December 31, 2023 and 2022.

| e. | Effective tax expense (benefit): |

The components of loss before tax and
a reconciliation of the Company’s income tax expense to the Company’s theoretical statutory tax benefit is as follows:

|                                                                                                                  |     | Year Ended December 31, |  2023 |   |     |   |  2022 |   |
|:-----------------------------------------------------------------------------------------------------------------|:----|:------------------------|------:|:--|:----|:--|------:|:--|
| Loss before taxes on income                                                                                      |     | $                       | 4,132 |   |     | $ | 1,449 |   |
| Israeli statutory income tax rate                                                                                |     |                         |  23.0 | % |     |   |  23.0 | % |
| Theoretical statutory tax benefit                                                                                |     |                         |   950 |   |     |   |   333 |   |
| Revaluation of convertible notes                                                                                 |     |                         |  (464 | ) |     |   |   (91 | ) |
| Temporary deductible difference                                                                                  |     |                         |   (26 | ) |     |   |   (94 | ) |
| Losses for which a valuation allowance was provided or benefit from loss carryforwards and permanent differences |     |                         |  (460 | ) |     |   |  (148 | ) |
| Income tax expense                                                                                               |     | $                       |     - |   |     | $ |     - |   |

<div align='center'>F-36</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004 and December 2015, the Company received funding                                                                  
 from the IIA for its participation in certain research and development activities, based on budgets approved by the IIA, subject to the 
 fulfillment of specified milestones. The Company is committed to pay royalties to the IIA on proceeds from sale of products related to  
 research and development